Skip to content
Search

Latest Stories

Macrolide taken during pregnancy may cause major birth defects: Study

The use of macrolide antibiotics during pregnancy is associated with an increased risk of major birth defects, according to a recent study.

The study, published in the BMJ, found that taking macrolide antibiotics during the first trimester increases the risk for any major malformation, specifically cardiovascular malformation, compared with penicillin-based antibiotics.


The researchers from the University College of London analysed data from 104,605 children born in the UK from 1990 to 2016 using the Clinical Practice Research Datalink (CPRD) with a median follow-up of 5.8 years after birth.

A further 82,314 children whose mothers were prescribed macrolides or penicillins before pregnancy, and 53, 735 children who were siblings of children in the study group acted as control (comparison) cohorts.

The study found major malformations in 186 children of 8,632 whose mothers were prescribed macrolides at any point during pregnancy and 1,666 of 95,973 children whose mothers were prescribed penicillin.

“Macrolide antibiotics are used to treat a wide variety of bacterial infections, and are among the most frequently prescribed antibiotics during pregnancy in Western countries,” said Heng Fan, Lead author, UCL Great Ormond Street Institute of Child Health.

“If the associations are shown to be causal, these findings suggest that an additional four children would be born with cardiovascular malformations for every 1,000 children exposed to macrolides instead of penicillins in the first trimester of pregnancy,” Fan said.

The study further revealed that macrolide prescribing in any trimester is linked with an increased risk of genital malformations and warned to take caution while using macrolides during pregnancy.

However, the authors underscored that “women should not stop taking antibiotics when needed,” but, if feasible, alternative antibiotics should be prescribed until further research is available.

More For You

GP surgery upgrades for annual appointments

The surgeries will have additional space to “see more patients, boost productivity and improve patient care”

Pic credit: iStock

GP surgery upgrades to create 8.3 million more annual appointments

Over 1,000 GP surgeries will have their premises modernised to meet the needs of a further 8.3 million appointments each year, the government has announced.

Backed by a cash injection of over £102 million, the surgeries will have additional space to “see more patients, boost productivity and improve patient care”.

Keep ReadingShow less
Wales boosts funding for pharmacy-led UTI and sore throat test services

The sore throat test (STTT) and treat service will be widely available

Pic credit: istock

Welsh pharmacies receive funding boost for clinical services

Two key clinical services will be available in 99 per cent of community pharmacies across Wales after a boost in funding.

The sore throat test (STTT) and treat service and the urinary tract infection (UTI) service have both benefitted from contractual negotiations between the Welsh Government and Community Pharmacy Wales (CPW).

Keep ReadingShow less
Paul Bennett
Paul Bennett, CEO, Royal Pharmaceutical Society
Paul Bennett, CEO, Royal Pharmaceutical Society

Pharmacists need to take advantage of independent prescribing pathways, says Bennett

Independent prescribing will be a “significant point” in the history of community pharmacy, according to Royal Pharmaceutical Society chief executive Paul Bennett.

Last month, the RPS announced the launch of a comprehensive new prescribing development programme to support pharmacists across all stages of their prescribing careers.

Keep ReadingShow less
Community Pharmacy Scotland secures £10m reimbursement uplift amid ongoing negotiations

Negotiations continue on the Global Sum element of remuneration.

Getty Images

Community Pharmacy Scotland secures £120m reimbursement deal for 2025/26

Community Pharmacy Scotland (CPS) has accepted the Scottish government’s initial financial offer for the 2025/26 fiscal year, securing a guaranteed minimum reimbursement of £120 million for community pharmacies — up from £110 million from 2024/25.

The agreement marks the first phase of ongoing negotiations surrounding community pharmacy funding for the upcoming financial year.

Keep ReadingShow less